JAZZ vs SXT · P/E 1988, rev $4.07B vs P/E 33, rev $1.61B
Jazz Pharmaceuticals PLC (JAZZ) versus Sensient Technologies Corporation (SXT) — a side-by-side from cached financials, not a winner call.
Jazz Pharmaceuticals PLC (JAZZ) is a biotechnology company listed on US.
Sensient Technologies Corporation (SXT) is a specialty chemicals company listed on NYSE.
Latest reported JAZZ revenue for 2024-12-31 was $4.07B. Net income was $560.1M. Revenue was up 6.1% from 2023-12-31 to 2024-12-31. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
Latest reported SXT revenue for 2025-12-31 was $1.61B. Net income was $134.5M. Revenue was up 3.5% from 2024-12-31 to 2025-12-31. SXT currently screens at market cap $4.73B and trailing P/E 32.9.
JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1. SXT currently screens at market cap $4.73B and trailing P/E 32.9.
Not investment advice. Open the JAZZ and SXT stock pages for the full models.
Not investment advice.